LSE:BXP
Beximco Pharmaceuticals Limited · LSE · Healthcare · GBP · FY for 2024
Figures on this page computed 2026-11-08 12:25 UTC
Last close
n/aGBp
Market data
7.6xP/E
Price / Earnings per Share (diluted)
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- GBp
- computed
- Computed from the filing for 2024
12.7%ROIC
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- GBp
- Computed from the filing for 2024
- Computed from the filing for 2024
- Computed from the filing for 2024
- Computed from the filing for 2024
- Computed from the filing for 2024
- Computed from the filing for 2024
13.1%Net margin
Net Income / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- GBp
- Computed from the filing for 2024
- Computed from the filing for 2024
13.8%FCF margin
Free Cash Flow / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- GBp
- Computed from the filing for 2024
- Computed from the filing for 2024
0.13Debt/equity
Total Debt / Shareholders' Equity
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- GBp
- Computed from the filing for 2024
- Computed from the filing for 2024
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- GBp
- computed
6 of 6 traits placed on the market's range. Nothing sits below its sector's middle.
Then and now
lens 3 of 9| Fact | 2014 | 2024 | Change |
|---|---|---|---|
| Sales | 11,206,885,677 | 44,391,604,000 | +296% |
| Profit | 1,528,297,573 | 5,829,529,000 | +281% |
| Free cash flow | -619,138,557 | 6,129,908,994 | +1,090% |
| Debt | 4,718,668,692 | 6,025,430,732 | +27.7% |
| Shares in issue | 446,112,090 | 446,112,000 | +0% |
The same five facts for 2014 and 2024, each read from the year's own filing.
The same five facts for 2014 and 2024, each read from the year's own filing.
Every figure in this lens
Except where said otherwise: Computed from the filing for 2014
Sales, 201411,206,885,677
- Source
- computed
- Statement
- income
- Fiscal year
- 2014
- Reported in
- BDT
Sales, 202444,391,604,000Computed from the filing for 2024
- Source
- computed
- Statement
- income
- Fiscal year
- 2024
- Reported in
- BDT
Profit, 20141,528,297,573
- Source
- computed
- Statement
- income
- Fiscal year
- 2014
- Reported in
- BDT
Profit, 20245,829,529,000Computed from the filing for 2024
- Source
- computed
- Statement
- income
- Fiscal year
- 2024
- Reported in
- BDT
Free cash flow, 2014-619,138,557
- Source
- computed
- Statement
- income
- Fiscal year
- 2014
- Reported in
- BDT
Free cash flow, 20246,129,908,994Computed from the filing for 2024
- Source
- computed
- Statement
- income
- Fiscal year
- 2024
- Reported in
- BDT
Debt, 20144,718,668,692
- Source
- computed
- Statement
- income
- Fiscal year
- 2014
- Reported in
- BDT
Debt, 20246,025,430,732Computed from the filing for 2024
- Source
- computed
- Statement
- income
- Fiscal year
- 2024
- Reported in
- BDT
Shares in issue, 2014446,112,090
- Source
- computed
- Statement
- income
- Fiscal year
- 2014
- Reported in
- BDT
Shares in issue, 2024446,112,000Computed from the filing for 2024
- Source
- computed
- Statement
- income
- Fiscal year
- 2024
- Reported in
- BDT